Biotech Values

[oc631]

The Roche-VRUS deal for RG7128 also has to be added to the table.

The limits to my computer editing skills have already been demonstrated. It's best left up to you.

You bring to mind a question asked by an analyst at VRUS' latest company presentation. He asked Schaefer Price if he thought RG7128 would work well with boceprevir in a DAA combo. He pointed out that Roche/Merck already teamed up to work together after boce approval. Price thought it was great idea but of course it was Roche's call not his.